Physician

Edith Garneau, M.D.

According to 2025 Medicare claims, Edith Garneau, M.D. (NPI: 1407085558) practices rheumatology in the Boston, MA market, with the plurality of this provider's patient population coming from Plymouth, MA. This provider's primary affiliated billing organization is AMERICAN ARTHRITIS & RHEUMATOLOGY ASSOCIATES MA PC (NPI: 1164041349; TIN: 84-4319867) and primary practice location at 02301-7153. Garneau is affiliated with the Prospect ACO Rhode Island (ACO ID: A4983), participating under the MSSP model.

Garneau's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 237 traditional Medicare patients, billed 30,685 HCPCS/CPT codes, and received $527,964 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,681 prescription claims across 251 beneficiaries totaling $522,156 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 104 records totaling $2,292. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $8,682 to $527,964. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	55	182	$8,682
2016	157	636	$28,876
2017	139	570	$24,975
2018	148	668	$33,983
2019	111	475	$20,974
2020	460	957	$58,658
2021	501	1,279	$90,154
2022	507	1,358	$86,383
2023	242	13,480	$284,766
2024	237	30,685	$527,964

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	46	109	$19,394
2016	161	800	$149,810
2017	203	1,769	$566,666
2018	236	1,977	$742,302
2019	295	1,743	$978,911
2020	426	1,997	$1,038,761
2021	492	3,424	$1,847,809
2022	480	3,194	$2,518,999
2023	241	1,422	$578,729
2024	251	1,681	$522,156

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	44	58	$143
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	62	62	$122
96413	Administration of chemotherapy into vein, 1 hour or less	36	176	$105
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	176	389	$95
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	87	128	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	26	812	$191,674
Orencia Clickject	Abatacept	16	448	$88,585
Actemra Actpen	Tocilizumab	13	364	$43,935
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	270	17,683	$11,003
Methotrexate	Methotrexate Sodium	192	10,281	$5,382

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	104	$2,292	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Edith Garneau, M.D.?

Tedicare shows public-source Medicare data for Edith Garneau, M.D. (NPI 1407085558), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Edith Garneau, M.D. have ACO affiliation data?

Edith Garneau, M.D. is shown with ACO affiliation data for Prospect ACO Rhode Island (MSSP, ACO ID A4983).

What billing organization is linked to Edith Garneau, M.D.?

Edith Garneau, M.D. is linked to AMERICAN ARTHRITIS & RHEUMATOLOGY ASSOCIATES MA PC (billing NPI 1164041349) in the available physician profile data.

Does Edith Garneau, M.D. have Open Payments data?

Edith Garneau, M.D. has 104 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.